Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Biosimilar Bill Prompts Formation of Nebraska Rheumatology Society

Kelly Tyrrell  |  March 1, 2018

Last year, Nebraska rheumatologist Marcus Snow, MD, learned a biosimilar bill was up for debate in his state legislature, yet “I had no knowledge of it,” he says.

Forming the Society
The bill “was something that caught my eye, and I thought there should be a mechanism in place to allow us to disseminate information quickly so our voice can be heard in the future,” says the University of Nebraska Medical Center rheumatologist.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Inspired by this event, as well as conversations he’d had through his involvement in the ACR’s Committee on Rheumatologic Care (CORC) and other colleagues, Dr. Snow decided it was time to create a state rheumatology society.

Dr. Snow emailed all 30 of his rheumatology colleagues in the state and asked whether they would be interested in forming and joining a representative society.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After “robust feedback,” in June 2017, Dr. Snow and seven others convened a conference call to discuss next steps. They held a second call in July, and by October, the Nebraska physicians had conducted their first organizational meeting as the Nebraska Rheumatology Society, attended by roughly half of the state’s practitioners.

There, they helped finalize the society’s bylaws. They had examined bylaws adopted by other state rheumatology societies, personalized them for Nebraska and then drafted a final version that was shared and voted upon via email.

In early February, the society determined the composition of its board, which includes a trainee member.

Determining a Focus
“We’ve talked among ourselves about what our focus should be, and we plan to take that back to our members and let them help decide where we put our efforts,” Dr. Snow says. The society would like to address advocacy issues as appropriate, contribute to growth in the rheumatology specialty and provide educational opportunities for members, which Dr. Snow hopes will ultimately include physicians’ assistants, nurse practitioners, medical students, residents and fellows.

“I think our organization can serve a lot of roles,” Dr. Snow says, noting it has already had conversations with the Rheumatology Society of Iowa and the Rheumatology Association of Minnesota and the Dakotas to explore ways to work together.

Joseph Nahas, MD, a rheumatologist at CHI Health and Creighton University Medical Center in Omaha, says that as busy clinicians, he and his colleagues often do not take the time to reach out and share ideas and perspectives with one another. He is excited for the opportunity the society offers to, “connect and share ideas and thoughts on the issues facing rheumatology and our patients today.”

Page: 1 2 | Single Page
Share: 

Filed under:Profiles Tagged with:Marcus SnowNebraska Rheumatology Societystate society

Related Articles
    Jennifer Elliott, MD

    The Nebraska Rheumatology Society Grows to Meet State’s Challenges

    May 15, 2020

    As state rheumatology societies go, the Nebraska Rheuma­tology Society (NRS) is one of the new kids on the block. Established two years ago, the NRS hopes to involve all 27 rheumatologists across the state. Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center (UNMC), Omaha, says the state’s rheumatologists are spread across…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    January 19, 2018

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences